IN2014CN04590A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04590A
IN2014CN04590A IN4590CHN2014A IN2014CN04590A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A IN 4590CHN2014 A IN4590CHN2014 A IN 4590CHN2014A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A
Authority
IN
India
Prior art keywords
nucleic acid
acid strand
nucleotides
nucleotide analogs
transcription product
Prior art date
Application number
Other languages
English (en)
Inventor
Takanori Yokota
Kazutaka Nishina
Satoshi Obika
Hidehiro Mizusawa
Original Assignee
Nat Univ Corp Tokyo Med & Dent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Corp Tokyo Med & Dent filed Critical Nat Univ Corp Tokyo Med & Dent
Publication of IN2014CN04590A publication Critical patent/IN2014CN04590A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
IN4590CHN2014 2011-12-16 2012-12-17 IN2014CN04590A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011275488 2011-12-16
PCT/JP2012/083180 WO2013089283A1 (fr) 2011-12-16 2012-12-17 Acide nucléique double brin chimérique

Publications (1)

Publication Number Publication Date
IN2014CN04590A true IN2014CN04590A (fr) 2015-09-18

Family

ID=47559626

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4590CHN2014 IN2014CN04590A (fr) 2011-12-16 2012-12-17

Country Status (9)

Country Link
US (5) US9816089B2 (fr)
EP (1) EP2791335B1 (fr)
JP (7) JP6112569B2 (fr)
CN (2) CN104126010B (fr)
AU (1) AU2012353330B2 (fr)
CA (2) CA2859581C (fr)
ES (1) ES2707232T3 (fr)
IN (1) IN2014CN04590A (fr)
WO (1) WO2013089283A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
IN2014CN04590A (fr) 2011-12-16 2015-09-18 Nat Univ Corp Tokyo Med & Dent
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
CA2901983A1 (fr) * 2013-03-01 2014-09-04 National University Corporation Tokyo Medical And Dental University Polynucleotides antisens monocatenaires chimeres et agent antisens bicatenaire
JP6300212B2 (ja) * 2013-03-21 2018-03-28 国立大学法人 東京医科歯科大学 二重鎖核酸結合剤、当該結合剤−二重鎖核酸複合体、当該複合体を含有する医薬品組成物、及び、当該複合体の製造方法
CA2915443A1 (fr) * 2013-06-16 2014-12-24 National University Corporation Tokyo Medical And Dental University Acide nucleique antisens a double brin ayant un effet de saut d'exon
WO2015105083A1 (fr) * 2014-01-07 2015-07-16 塩野義製薬株式会社 Oligonucléotide double brin contenant un oligonucléotide antisens et un dérivé de sucre
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
US11116843B2 (en) 2015-09-25 2021-09-14 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2017068791A1 (fr) * 2015-10-23 2017-04-27 レナセラピューティクス株式会社 Complexe d'acide nucléique présentant au moins une structure renflée
EP3366773A4 (fr) * 2015-10-23 2019-06-12 Rena Therapeutics Inc. Complexe d'acides nucléiques
JP6950958B2 (ja) * 2015-12-01 2021-10-13 国立大学法人 東京医科歯科大学 核酸を含む経腸投与用組成物
US11530409B2 (en) * 2016-01-26 2022-12-20 Nissan Chemical Corporation Single-stranded oligonucleotide
MA45328A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
JP7043078B2 (ja) * 2016-09-23 2022-03-29 国立大学法人 東京医科歯科大学 血液脳関門通過型ヘテロ２本鎖核酸
JP7129702B2 (ja) 2016-09-29 2022-09-02 国立大学法人 東京医科歯科大学 オーバーハングを有する二本鎖核酸複合体
US11572558B2 (en) 2017-02-06 2023-02-07 Nissan Chemical Corporation Single-stranded oligonucleotide
JP7190794B2 (ja) 2017-03-29 2022-12-16 塩野義製薬株式会社 核酸医薬及び多分岐脂質の複合体
WO2018180005A1 (fr) * 2017-03-31 2018-10-04 国立研究開発法人日本医療研究開発機構 Acide nucléique antisens pour l'inhibition de la biosynthèse de sulfate de chondroïtine
JP6974872B2 (ja) * 2017-06-30 2021-12-01 国立大学法人 東京医科歯科大学 ヘテロ二本鎖型ａｎｔｉｍｉＲ
TW201920671A (zh) 2017-07-26 2019-06-01 日商日產化學股份有限公司 單股寡核苷酸
JP7360170B2 (ja) 2018-02-28 2023-10-12 国立大学法人 東京医科歯科大学 虚血病変部位特異的な遺伝子治療法
EP3769769A4 (fr) * 2018-03-19 2022-05-04 National University Corporation Tokyo Medical and Dental University Acide nucléique à toxicité réduite
KR20190110043A (ko) * 2018-03-19 2019-09-27 주식회사 케이티 비디오 신호 처리 방법 및 장치
JPWO2019182037A1 (ja) 2018-03-20 2021-03-11 国立大学法人東京工業大学 毒性が低減されたアンチセンスオリゴヌクレオチド
WO2019182109A1 (fr) * 2018-03-22 2019-09-26 国立大学法人東京医科歯科大学 Ligand lipidique franchissant la barrière hémato-encéphalique (bbb) à base d'un acide hétéronucléique
EP3911747A4 (fr) * 2019-01-18 2023-05-24 University Of Massachusetts Ancres de modification pharmacocinétique dynamique
US20220175817A1 (en) * 2019-04-08 2022-06-09 National University Corporation Tokyo Medical And Dental University Pharmaceutical Composition for Treating Muscle Disease
US20220267778A1 (en) 2019-07-30 2022-08-25 Shionogi & Co., Ltd. Nucleic acid drug targeting murf1
US20240117346A1 (en) * 2019-10-11 2024-04-11 National University Corporation Tokyo Medical And Dental University Modified hetero nucleic acids
US20230061751A1 (en) * 2020-01-17 2023-03-02 University Of Massachusetts Universal dynamic pharmacokinetic-modifying anchors
CN114929876A (zh) 2020-01-31 2022-08-19 株式会社三和化学研究所 Atn1的反义寡核苷酸
JPWO2021177418A1 (fr) 2020-03-04 2021-09-10
WO2021187392A1 (fr) * 2020-03-16 2021-09-23 国立大学法人東京医科歯科大学 Acide hétéro-nucléique contenant un acide nucléique morpholino
JPWO2021256297A1 (fr) 2020-06-15 2021-12-23
EP4247949A1 (fr) 2020-11-23 2023-09-27 Alpha Anomeric SAS Duplex d'acides nucléiques
WO2022183102A1 (fr) * 2021-02-26 2022-09-01 Northwestern University Biocapteurs acellulaires avec circuits de deplacement de brins d'adn
WO2022250050A1 (fr) 2021-05-25 2022-12-01 国立大学法人東京医科歯科大学 Acide hétéro-nucléique à teneur en ｓｃｐｂｎａ ou ａｍｎａ
AU2022285344A1 (en) 2021-05-31 2023-12-14 Rena Therapeutics Inc. Ligand-bound nucleic acid complex
WO2023022229A1 (fr) 2021-08-19 2023-02-23 国立大学法人東京医科歯科大学 Acide héteronucléique modifié contenant de l'acide nucléique morpholino
WO2023026994A1 (fr) 2021-08-21 2023-03-02 武田薬品工業株式会社 Conjugué peptide-médicament liant le récepteur de la transferrine humaine
WO2023042876A1 (fr) * 2021-09-15 2023-03-23 国立大学法人東京医科歯科大学 Acide hétéronucléique comprenant un nucléoside 2'-modifié
WO2023105898A1 (fr) * 2021-12-07 2023-06-15 リードファーマ株式会社 Complexe d'oligonucléotide antisens

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110894A (ja) * 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2002249967A1 (en) * 2001-11-12 2003-05-26 Epiclone, Inc. Gene silencing using sense dna and antisense rna hybrid constructs
DE10240417A1 (de) 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
US20040137471A1 (en) * 2002-09-18 2004-07-15 Timothy Vickers Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds
CA2505801A1 (fr) 2002-11-13 2004-05-27 Rosanne Crooke Modulation antisens de l'expression d'apolipoproteine b
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 Ｎ−ｏ結合性架橋構造型新規人工核酸
EP2256201A3 (fr) * 2003-09-18 2012-07-04 Isis Pharmaceuticals, Inc. Modulation de l'expression de eIF4E
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
WO2005113571A2 (fr) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methodes de delivrance de composes d'oligomeres
CN101124339A (zh) 2004-12-30 2008-02-13 托德·M·豪泽 使用自我保护寡核苷酸调节基因表达的组合物和方法
CA3044969A1 (fr) 2006-05-05 2007-12-21 Ionis Pharmaceuticals, Inc. Composes et procedes de modulation de l'expression genique
SG174071A1 (en) 2006-08-10 2011-09-29 Oncotherapy Science Inc Genes and polypeptides relating to breast cancers
WO2008029619A1 (fr) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
JP2010505432A (ja) 2006-10-09 2010-02-25 サンタリス ファーマ アー／エス Ｐｃｓｋ９を調節するためのｒｎａアンタゴニスト化合物
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US7858592B2 (en) * 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
EP2134736A4 (fr) * 2007-03-15 2013-05-29 Jyoti Chattopadhyaya Ribothymidines carbocycliques 2', 4' à conformation verrouillée à 5 et 6 éléments destinées à traiter des infections et le cancer
EP2133425A1 (fr) * 2008-06-13 2009-12-16 Karin Mölling Procédé et composé de thérapie antivirale (VIH)
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
EP3252068A3 (fr) * 2009-10-12 2018-03-14 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
IN2014CN04590A (fr) 2011-12-16 2015-09-18 Nat Univ Corp Tokyo Med & Dent

Also Published As

Publication number Publication date
JP2020039364A (ja) 2020-03-19
EP2791335B1 (fr) 2018-11-14
US9816089B2 (en) 2017-11-14
JP2022171811A (ja) 2022-11-11
CA3106312A1 (fr) 2013-06-20
US11034955B2 (en) 2021-06-15
EP2791335A1 (fr) 2014-10-22
CN104126010B (zh) 2021-04-06
US20140302603A1 (en) 2014-10-09
JP6638923B2 (ja) 2020-02-05
JP2021011501A (ja) 2021-02-04
US10329567B2 (en) 2019-06-25
CA2859581A1 (fr) 2013-06-20
AU2012353330A1 (en) 2014-07-31
JP2015502134A (ja) 2015-01-22
US20210340540A1 (en) 2021-11-04
JP6960123B2 (ja) 2021-11-05
US10337006B2 (en) 2019-07-02
CN104126010A (zh) 2014-10-29
ES2707232T3 (es) 2019-04-03
US20180073024A1 (en) 2018-03-15
JP2017140031A (ja) 2017-08-17
CN112386605A (zh) 2021-02-23
JP7423015B2 (ja) 2024-01-29
JP2022000426A (ja) 2022-01-04
WO2013089283A1 (fr) 2013-06-20
JP2018203779A (ja) 2018-12-27
AU2012353330B2 (en) 2018-04-19
US20190270996A1 (en) 2019-09-05
JP6112569B2 (ja) 2017-04-12
JP6416301B2 (ja) 2018-10-31
US20180320181A1 (en) 2018-11-08
CA2859581C (fr) 2022-03-22
JP7174384B2 (ja) 2022-11-17

Similar Documents

Publication Publication Date Title
IN2014CN04590A (fr)
EP2580355A4 (fr) Transcription inverse à médiation par un oligonucléotide à tige-boucle modifié et pcr quantitative restreinte à espacement de bases
IN2013MN00522A (fr)
EP4086347A3 (fr) Composés antisens sélectifs et leurs utilisations
MX2021015290A (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
WO2010080129A3 (fr) Agents allongés servant de substrats de dicer et procédés d'inhibition spécifique de l'expression d'un gène
NZ627060A (en) Polynucleotide molecules for gene regulation in plants
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
MX342195B (es) Nucleótidos de terminación de rápida fotodescomposición 5-metoxi, 3' -oh no bloqueados y métodos para secuenciación de ácido nucleico.
WO2012142611A3 (fr) Séquençage de petites quantités d'acides nucléiques complexes
EP4269584A3 (fr) Composés antisens sélectifs et leurs utilisations
NZ601247A (en) Targeted genomic alteration
JP2012050447A5 (fr)
WO2012046085A3 (fr) Procédés de déclenchement de la production d'insuline
WO2012168307A3 (fr) Efficacité améliorée de recombinaison par inhibition d'une réparation de l'adn par nhej
WO2013010062A3 (fr) Réduction de la complexité d'acide nucléique
WO2015073978A3 (fr) Procédés de détection multiplex d'allèles associés à des affections ophtalmiques
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
WO2012078967A3 (fr) Compositions et procédés pour l'augmentation de la production d'érythropoïétine (epo)
WO2010006973A3 (fr) Compositions et procédés pour inhiber l’expression de gènes de récepteur tgf-bêta
IN2014DN07878A (fr)
WO2012178033A3 (fr) Arnsi de serpina1 : compositions et méthodes de traitement
WO2009086428A3 (fr) Procédés et compositions destinés à augmenter l'expression génique
Kaur et al. Reduction in carotenoid levels in the marine diatom Phaeodactylum tricornutum by artificial microRNAs targeted against the endogenous phytoene synthase gene
WO2007147067A3 (fr) Procédés et compositions de régulation de l'évolution du cycle cellulaire